Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $1,742,812.50 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 31,250 shares of the firm’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $55.77, for a total value of $1,742,812.50. Following the transaction, the insider now directly owns 170,237 shares of the company’s stock, valued at approximately $9,494,117.49. This represents a 15.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Tuesday, December 10th, Timothy Rolph sold 4,818 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.91, for a total value of $148,924.38.

Akero Therapeutics Stock Performance

Shares of Akero Therapeutics stock opened at $54.08 on Friday. Akero Therapeutics, Inc. has a one year low of $15.32 and a one year high of $58.40. The firm has a market capitalization of $3.77 billion, a price-to-earnings ratio of -14.42 and a beta of -0.19. The business has a 50-day simple moving average of $30.26 and a 200 day simple moving average of $28.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). On average, research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on AKRO. HC Wainwright raised their target price on Akero Therapeutics from $50.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $35.00 to $63.00 in a research report on Thursday. UBS Group lifted their price objective on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research report on Friday. Citigroup lifted their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Canaccord Genuity Group lifted their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a research report on Tuesday. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Akero Therapeutics has an average rating of “Buy” and an average price target of $75.86.

Hedge Funds Weigh In On Akero Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its stake in Akero Therapeutics by 54.4% during the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock valued at $226,554,000 after purchasing an additional 2,782,029 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Akero Therapeutics by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock valued at $203,053,000 after purchasing an additional 201,225 shares during the last quarter. RTW Investments LP boosted its stake in Akero Therapeutics by 9.0% during the 3rd quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock valued at $169,829,000 after purchasing an additional 487,450 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Akero Therapeutics during the 3rd quarter valued at about $37,392,000. Finally, SG Americas Securities LLC boosted its stake in Akero Therapeutics by 4,022.1% during the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock valued at $16,636,000 after purchasing an additional 583,486 shares during the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.